Sowing Seeds In Drug Discovery The Evotec Way: CEO Werner Lanthaler
Executive Summary
Evotec's hybrid drug discovery model continues to attract pharma partners and generate internal assets using what its CEO calls a "diversified seed sowing" business approach.
You may also be interested in...
Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships
Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.
Sanofi’s Larsen On Advances In Diabetes R&D And Payer Expectations
Dr Philip Larsen, Vice President, Research and Translational Medicine, R&D Diabetes Division, Sanofi tells Scrip in an interview which way potential gene therapy for diabetes may be headed and how the Sanofi-Evotec alliance is shaping. He also indicates that oral insulin, considered the holy grail of diabetes treatment, is a ‘really long journey’ with difficult prospects currently.
The Regenerative Market Brings The Future Closer
A clear sign the regenerative medicine and therapy market is making considerable progress comes from the amount of investor funding pouring into the space, and although a lot of the technology is still spoken about in the future tense, a variety of new companies are bringing the future much closer. An additional hallmark of the market is the role device companies are finding for themselves in an industry primarily lead by pharmaceutical businesses.